Computational prediction of neoantigens: do we need more data or new approaches?

Abstract

Personalized cancer immunotherapy may benefit from improved computational algorithms for identifying neoantigens. Recent results demonstrate that machine learning can improve accuracy. Additional improvements may require more genomic data paired with in vitro T cell reactivity measurements, and more sophisticated algorithms that take into account T cell receptor specificity.